TWST: What are the messages you wish to convey to them?
Mr. Koly: This company is for real. It is tremendously undervalued at the moment, with a valuation in the $20-million range. This is very low for a company in a Phase III human clinical pivotal study for a technology that, potentially, will address a deadly disease for which there is currently no effective treatment. We are not claiming to have a cure for cancer, but we are claiming that, with this drug delivery system, we can extend life for many of these patients. We intend to prove that through our clinical studies. The Delcath system may offer a very substantial improvement in the quality of life of cancer patients who are undergoing chemotherapy treatment, including a significant reduction in side effects.